本帖最后由 老马 于 2012-1-13 21:20 编辑
+ C& _% I( j( c4 ]. {
5 d5 _7 B' G4 b. m8 j爱必妥和阿瓦斯丁的比较0 f3 {2 `! f/ H5 z2 x3 n( Y, [$ o
# y) h" q3 `; t8 t1 w
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/" u8 b! Y/ R6 h7 k' g- O$ u
( c* D, i; [+ s1 O, s9 _6 i! @
, U7 Q- j9 e: hhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
6 C; U) Q: M2 R, H2 l8 h; X==================================================
$ Q$ K Y3 G( H- v0 dOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)( F. D/ J: X. n) K+ a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.# }1 h7 g: a; Q; Z! ]1 ~$ s* _
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
j Q5 L2 L' N+ t& u
|